Xyratex (XRTX) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

Stock Analysis Analyst Forecasts Competitors Earnings Headlines Short Interest Trends

XRTX vs. UPC, AVTX, KPRX, GHSI, VAXX, CMMB, LUMO, MNPR, IMNN, and ERNA

Should you be buying Xyratex stock or one of its competitors? The main competitors of Xyratex include Universe Pharmaceuticals (UPC), Avalo Therapeutics (AVTX), Kiora Pharmaceuticals (KPRX), Guardion Health Sciences (GHSI), Vaxxinity (VAXX), Chemomab Therapeutics (CMMB), Lumos Pharma (LUMO), Monopar Therapeutics (MNPR), Imunon (IMNN), and Eterna Therapeutics (ERNA). These companies are all part of the "pharmaceutical preparations" industry.

Xyratex vs.

Xyratex (NASDAQ:XRTX) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

: Xyratex received 156 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
Company Underperform Outperform
Xyratex Outperform Votes
156
63.41%
Underperform Votes
90
36.59%
Universe Pharmaceuticals N/A N/A
: Xyratex currently has a consensus price target of $14.00, suggesting a potential upside of 700.00%. Given Xyratex's higher probable upside, equities analysts plainly believe Xyratex is more favorable than Universe Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xyratex
0 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
Universe Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Universe Pharmaceuticals' return on equity of 0.00% beat Xyratex's return on equity.
Company Net Margins Return on Equity Return on Assets
Xyratex N/A -135.54% -107.64%
Universe Pharmaceuticals N/A N/A N/A
: 0.2% of Xyratex shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 6.9% of Xyratex shares are owned by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Xyratex has higher earnings, but lower revenue than Universe Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xyratex N/A N/A -$2.16M -$1.34 -1.31
Universe Pharmaceuticals $32.31M 0.42 -$6.16M N/A N/A
: Xyratex has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.
: In the previous week, Xyratex had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 2 mentions for Xyratex and 0 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.15 beat Xyratex's score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Xyratex Neutral
Universe Pharmaceuticals Neutral

Company	Underperform	Outperform
Xyratex	Outperform Votes 156 63.41%	Underperform Votes 90 36.59%
Universe Pharmaceuticals	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xyratex	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Universe Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Net Margins	Return on Equity	Return on Assets
Xyratex	N/A	-135.54%	-107.64%
Universe Pharmaceuticals	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xyratex	N/A	N/A	-$2.16M	-$1.34	-1.31
Universe Pharmaceuticals	$32.31M	0.42	-$6.16M	N/A	N/A

Company	Overall Sentiment
Xyratex	Neutral
Universe Pharmaceuticals	Neutral

Summary

Xyratex and Universe Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Ad Porter & Company

Nvidia insiders dumping shares

All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.

To see Porter Stansberry's new AI prediction go here now.

Get Xyratex News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XRTX vs. The Competition

Export to Excel

Metric	Xyratex	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.50M	$7.07B	$5.29B	$8.21B
Dividend Yield	N/A	2.82%	2.72%	3.97%
P/E Ratio	-1.31	21.65	155.18	18.65
Price / Sales	N/A	317.62	2,087.66	91.84
Price / Cash	N/A	32.58	35.71	34.11
Price / Book	0.75	5.89	4.94	4.51
Net Income	-$2.16M	$147.89M	$111.73M	$216.36M

Xyratex Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPC Universe Pharmaceuticals	0 of 5 stars 0.00 / 5 stars	$3.71 -6.1%	N/A	+76.1%	$13.45M	$32.31M	0.00	225	Gap Up High Trading Volume
AVTX Avalo Therapeutics	1.0586 of 5 stars 1.06 / 5 stars	$12.78 +2.2%	N/A	-78.5%	$13.21M	$1.92M	0.00	19	Upcoming Earnings Short Interest ↓ Gap Up
KPRX Kiora Pharmaceuticals	3.7163 of 5 stars 3.72 / 5 stars	$4.50 +9.8%	$18.00 +300.0%	-12.9%	$13.13M	N/A	0.00	10	Analyst Forecast Short Interest ↓ Analyst Revision News Coverage Positive News High Trading Volume
GHSI Guardion Health Sciences	0 of 5 stars 0.00 / 5 stars	$9.93 +3.5%	N/A	+30.7%	$12.75M	$12.25M	-2.47	9	Short Interest ↓
VAXX Vaxxinity	0 of 5 stars 0.00 / 5 stars	$0.10 -50.0%	$7.00 +6,900.0%	-97.7%	$12.67M	$70,000.00	-0.22	57	Gap Up
CMMB Chemomab Therapeutics	2.7127 of 5 stars 2.71 / 5 stars	$1.12 -0.9%	$5.67 +406.0%	-9.2%	$12.38M	N/A	-0.70	20	News Coverage Gap Up
LUMO Lumos Pharma	1.6041 of 5 stars 1.60 / 5 stars	$1.46 +0.7%	$18.00 +1,132.9%	-51.6%	$11.85M	$1.53M	-0.32	33	Upcoming Earnings Short Interest ↑ News Coverage
MNPR Monopar Therapeutics	3.8027 of 5 stars 3.80 / 5 stars	$0.68 -5.6%	$2.00 +196.3%	-11.0%	$11.80M	N/A	-1.30	9	Short Interest ↓ Positive News Gap Down
IMNN Imunon	3.1556 of 5 stars 3.16 / 5 stars	$1.25 -13.2%	$12.00 +860.0%	-9.4%	$11.75M	$500,000.00	-0.62	30	Short Interest ↓ High Trading Volume
ERNA Eterna Therapeutics	0 of 5 stars 0.00 / 5 stars	$2.15 +0.9%	N/A	-37.7%	$11.63M	$70,000.00	-0.51	8	Short Interest ↓